DJIA 16,027.05 -177.92 -1.10%
NASDAQ 4,283.75 -79.39 -1.82%
S&P 500 1,853.44 -26.61 -1.42%
market minute promo

1.74 -0.10 (-5.43%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

OREX $1.74 -5.43%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.81
Previous Close $1.84
Daily Range $1.68 - $1.83
52-Week Range $1.39 - $9.37
Market Cap $253.1M
P/E Ratio -4.72
Dividend (Yield) $0.00 (0.0%)
Volume 1,425,011
Average Daily Volume 1,581,092
Current FY EPS -$0.52




Drug Makers

Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website:

News & Commentary

Biotech's Dumbest CEO Moves in 2015

Which biotech CEOs are most ready to forget 2015?

Orexigen Investors Get Glimpse Of Potential And Problems With Contrave Revenue

Vivus - Qsymia Sales Move Up - Does It Matter?

Orexigen - Contrave Sales Dip Again

Orexigen: Year Over Year Growth For Contrave Is In Jeopardy

Why Zafgen Inc's Stock Is in the Red Today

Shares took a nose dive on Monday after an investment firm published a short report on the company.

Vivus- Qsymia Sales Starting Off 2016 With Fizzle

3 Stocks I Would Avoid at All Costs

Some stocks are just plain awful. Here are three that investors shouldn't touch with a 10-foot pole.

Arena- Belviq Sales Slip In Second Week Of New Year

Why Shares of Zafgen Skyrocketed Today

The drugmaker's experimental treatment for Prader-Willi Syndrome met its co-primary endpoints in a late-stage study.

See More OREX News...

OREX's Top Competitors

OREX $1.74 (-5.43%)
Current stock: OREX
AMGN $143.00 (-1.41%)
Current stock: AMGN
GILD $85.26 (0.14%)
Current stock: GILD
BIIB $250.77 (-4.96%)
Current stock: BIIB